US Office Relocation to California
MELBOURNE, Australia, July 10 /PRNewswire/ -- Cytopia (ASX: CYT) announced today the appointment of Dr. Devron Averett as Chief Scientific Advisor to the company.
Based in California, USA, Dr. Averett will work closely with the company's executive management team, on a part-time basis during this year, to provide scientific leadership and guidance. He has held global leadership roles at Glaxo Wellcome and Burroughs Wellcome and in recent years, at Valeant Pharmaceuticals International and Anadys Pharmaceuticals, Inc, a company he co-founded.
Holding a Ph.D. in Microbiology and Immunology, Dr. Averett has authored or coauthored over 40 peer-reviewed publications and numerous presentations. He is an inventor on 17 issued and nine pending US patents, and their corresponding international filings. His work has contributed to the discovery or development of multiple oncology and antiviral medicines and drug candidates, including Zeffix, Emtriva, Ziagen, Arranon, and most recently ANA598 for HCV and ANA773 in oncology.
"We are extremely pleased to have secured the services of Dr. Averett," said Cytopia CEO, Mr. Andrew Macdonald. "His contribution will bolster the work currently underway on our range of small molecule compounds that are both approaching the clinic and progressing through clinical trials."
Cytopia Inc is consolidating its North American operations in Woodside, California and closing the Rensselaer, New York office, which is currently led by Dr. Shreefal Mehta as VP Business and Corporate Development. Dr. Mehta has chosen not to relocate to the West Coast and will leave Cytopia Inc at the end of July, 2008. The company is grateful for his considerable contributions.
Mr. Richard Haiduck, who has been working with the company in a
strategic consulting role, has been appointed as Chief Business Advisor,
with responsibility for Cytopia's global business and corpo
Copyright©2008 PR Newswire.
All rights reserved